What is Caris Life Sciences?
Founded in 2008, Caris Life Sciences operates at the intersection of biotechnology and data science. The company is a pioneer in the field of precision medicine, providing physicians and patients with actionable insights derived from complex molecular and genomic data. By trailblazing new paths in disease diagnostics, Caris enables highly personalized treatment strategies, effectively transforming how healthcare providers approach oncology and other critical medical conditions. Its market position is defined by its proprietary technology platform, which integrates multi-omics data to deliver high-quality, evidence-based information that is essential for modern clinical decision-making.
How much funding has Caris Life Sciences raised?
Caris Life Sciences has raised a total of $3.6B across 7 funding rounds:
Unspecified
$150M
Unspecified
$310M
Other Financing Round
$830M
Debt
$400M
Other Financing Round
$168M
IPO
$494M
Debt
$1.2B
Unspecified (2018): $150M with participation from Sixth Street Partners
Unspecified (2020): $310M led by Coatue Management, T. Rowe Price Associates, First Light Asset Management, Highland Capital Management , L.P., Neuberger Berman, ClearBridge Investments, OrbiMed, and Millennium Management
Other Financing Round (2021): $830M supported by Fidelity Management, OrbiMed, CPP Investments, ClearBridge Investments, Sixth Street, Tudor Investment Corporation, Columbia Threadneedle, Silver Lake, T. Rowe Price, Neuberger Berman, Eaton Vance Management, Rock Springs Capital, Coatue, Millennium, Pura Vida Investments, Highland Capital Management, and First Light Asset Management
Debt (2023): $400M featuring OrbiMed and Braidwell
Other Financing Round (2025): $168M backed by Woodline Partners, Braidwell, Ghisallo Capital Management, and Perceptive Advisors
IPO (2025): $494M, investors not publicly disclosed
Debt (2026): $1.2B led by Blackstone and Blue Owl
Key Investors in Caris Life Sciences
OrbiMed
OrbiMed is a specialized investment firm focused on the healthcare sector, managing capital across biopharmaceuticals, medical devices, and diagnostics to support innovation cycles.
Sixth Street Partners
Sixth Street is a global investment firm providing flexible, long-term capital and innovative solutions to companies across diverse sectors including healthcare and software.
Coatue Management
Coatue Management is an employee-owned hedge fund sponsor that invests in both public and private equity, with a strong focus on technology and high-growth sectors.
What's next for Caris Life Sciences?
With the recent influx of $1.2B, Caris Life Sciences is well-positioned to accelerate its operational expansion and deepen its investment in data-driven healthcare innovation. The company is expected to focus on enhancing its diagnostic capabilities and expanding its footprint in the precision medicine market. By leveraging this strategic capital, Caris aims to further refine its technological infrastructure, ensuring that its data-informed insights remain at the forefront of clinical practice. As the firm moves into its next phase of growth, the focus will likely remain on scaling its platform to meet the increasing demand for personalized healthcare solutions, while maintaining its commitment to improving patient lives through rigorous scientific research and technological advancement.
See full Caris Life Sciences company page
